SG10202112047TA - Immunogenic antigen identification from a pathogen and correlation to clinical efficacy - Google Patents

Immunogenic antigen identification from a pathogen and correlation to clinical efficacy

Info

Publication number
SG10202112047TA
SG10202112047TA SG10202112047TA SG10202112047TA SG10202112047TA SG 10202112047T A SG10202112047T A SG 10202112047TA SG 10202112047T A SG10202112047T A SG 10202112047TA SG 10202112047T A SG10202112047T A SG 10202112047TA SG 10202112047T A SG10202112047T A SG 10202112047TA
Authority
SG
Singapore
Prior art keywords
pathogen
correlation
clinical efficacy
immunogenic antigen
antigen identification
Prior art date
Application number
SG10202112047TA
Inventor
Ann Marie Leen
Pailbel Aguayo-Hiraldo
Ifigeneia Tzannou
Juan F Valdes Vera
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of SG10202112047TA publication Critical patent/SG10202112047TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
SG10202112047TA 2015-09-18 2016-09-19 Immunogenic antigen identification from a pathogen and correlation to clinical efficacy SG10202112047TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562220884P 2015-09-18 2015-09-18

Publications (1)

Publication Number Publication Date
SG10202112047TA true SG10202112047TA (en) 2021-12-30

Family

ID=58289728

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10202112047TA SG10202112047TA (en) 2015-09-18 2016-09-19 Immunogenic antigen identification from a pathogen and correlation to clinical efficacy

Country Status (10)

Country Link
US (2) US11167024B2 (en)
EP (1) EP3350600A4 (en)
JP (3) JP6999941B2 (en)
CN (3) CN113943703A (en)
AU (2) AU2016324479B2 (en)
CA (1) CA2998649A1 (en)
HK (1) HK1258649A1 (en)
IL (2) IL258090B2 (en)
SG (1) SG10202112047TA (en)
WO (1) WO2017049291A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
WO2013119947A1 (en) 2012-02-09 2013-08-15 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
CN113943703A (en) 2015-09-18 2022-01-18 贝勒医学院 Identification of immunogenic antigens from pathogens and correlation with clinical efficacy
AU2020247987A1 (en) * 2019-03-25 2021-11-11 Baylor College Of Medicine Multi-respiratory virus antigen-specific T cells and methods of making and using the same therapeutically
EP3976068A4 (en) * 2019-05-31 2023-08-09 Children's National Medical Center Cytokine cocktails for selective expansion of t cell subsets
KR20220048021A (en) 2019-08-16 2022-04-19 베이롤 칼리지 오브 메드신 Third party virus-specific T cell compositions, methods for their preparation and methods for their use in antiviral prophylaxis
WO2021119293A2 (en) * 2019-12-10 2021-06-17 Children's National Medical Center T-cell epitopes of human parainfluenza virus 3 for adoptive t-cell immunotherapy
US20230028788A1 (en) * 2019-12-23 2023-01-26 Baylor College Of Medicine T cell performance assay as a prognostic factor for clinical outcome
WO2022192402A1 (en) * 2021-03-10 2022-09-15 Avail Bio, Inc. Methods, compositions, and systems for b-cell isolation sequencing

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641628A (en) 1989-11-13 1997-06-24 Children's Medical Center Corporation Non-invasive method for isolation and detection of fetal DNA
WO1994002156A1 (en) 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate t cells
US6821778B1 (en) 1993-12-01 2004-11-23 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells
JPH09510211A (en) 1994-03-08 1997-10-14 ダナ−ファーバー・キャンサー・インスティテュート Method of regulating T cell unresponsiveness
AUPM446594A0 (en) 1994-03-16 1994-04-14 Csl Limited Cytotoxic t-cell epitopes identified within epstein-barr virus
WO1995027722A1 (en) 1994-04-06 1995-10-19 Immunex Corporation Interleukin-15
EP0804210B1 (en) 1994-05-16 2002-11-27 Boehringer Mannheim Gmbh Method of immunomodulation by means of adoptive transfer of antigen-specific cytotoxic t-cells
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
EP0747481B1 (en) 1995-06-06 2001-12-19 Organon Teknika B.V. Epstein-Barr virus peptides and antibodies against these peptides
FR2745185B1 (en) 1996-02-28 1998-05-15 Sanofi Sa USE OF IL-7 IN THE TREATMENT OF AUTOIMMUNE DISEASES, PARTICULARLY INSULIN-DEPENDENT DIABETES MELLITUS
US6699477B2 (en) 1996-05-24 2004-03-02 The Council Of The Queensland Institute Of Medical Research EBV CTL epitopes
US5962318A (en) 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy
EP1012238A4 (en) 1997-01-31 2003-03-05 Epimmune Inc Peptides and peptide-loaded antigen presenting cells for the activation of ctl
WO1998049270A1 (en) 1997-04-25 1998-11-05 The Wistar Institute Of Anatomy And Biology Cytolytic t-cell clones against colorectal carcinoma and methods of use thereof
US7951383B2 (en) * 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
DE69840739D1 (en) 1997-10-27 2009-05-28 Merix Bioscience Inc Method and composition for the production of mature dendritic cells
US20020155108A1 (en) 1998-05-04 2002-10-24 Biocrystal, Ltd. Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells
US6828147B1 (en) 1999-02-24 2004-12-07 The Wistar Institute Of Anatomy And Biology Method of modifying cytotoxic cells and uses thereof
EP1155115A4 (en) 1999-02-24 2002-03-27 Wistar Inst Method of modifying cytotoxic cells and uses thereof
US7005131B1 (en) 1999-08-13 2006-02-28 The Rockefeller University Protective antigen of Epstein Barr Virus
US20150037297A1 (en) 1999-08-30 2015-02-05 David S Terman Sickled Erythrocytes and Progenitors Target Cytotoxics to Tumors
WO2001037671A1 (en) 1999-11-24 2001-05-31 Hope Ernest G Anti-angiogenic cellular agent for cancer therapy
DE10009341A1 (en) 2000-02-22 2001-09-06 Florian Kern Method for antigen-specific stimulation of T lymphocytes
US20020155127A1 (en) 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
JP5184732B2 (en) 2000-06-19 2013-04-17 ベス イスラエル デアコネス メディカル センター Compositions and methods of use of monoclonal and polyclonal antibodies specific for T cell subpopulations
ATE371017T1 (en) 2000-09-15 2007-09-15 Ortho Mcneil Pharm Inc COMPOSITIONS AND METHODS FOR TRIGGERING SPECIFIC CYTOLYTIC T CELL RESPONSES
EP1229043A1 (en) 2001-01-30 2002-08-07 Cyto-Barr B.V. Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith
GB0107628D0 (en) 2001-03-27 2001-05-16 Avidex Ltd Substances
US20040022761A1 (en) 2001-05-11 2004-02-05 Banchereau Jacques F Compositions and methods for producing antigen-presenting cells
CA2447593C (en) 2001-05-15 2014-07-08 Ortho-Mcneil Pharmaceutical, Inc. Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
DK1429597T3 (en) 2001-09-28 2006-05-01 Heinrich-Guenter Schumacher Cutting knife with one of the rails composed of a knife rail
JP2005536982A (en) 2001-11-07 2005-12-08 麒麟麦酒株式会社 T cell amplification in vitro and amplified T cell population
US20030148982A1 (en) 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
ATE446106T1 (en) 2001-11-29 2009-11-15 Dandrit Biotech As PHARMACEUTICAL COMPOSITION FOR TRIGGERING AN IMMUNE RESPONSE IN A HUMAN OR AN ANIMAL
US20040096457A1 (en) 2001-12-11 2004-05-20 Huber Brigitte T Treatment and prevention of ebv infection and ebv-associated disorders
AU2003202908A1 (en) 2002-01-03 2003-07-24 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US20070048329A1 (en) 2002-11-07 2007-03-01 Rajiv Khanna Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
AU2002953238A0 (en) 2002-12-09 2003-01-02 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland In vitro immunization
IL158140A0 (en) 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
EP1687400A4 (en) 2003-10-08 2009-01-07 Wolf Wilson Mfg Corp Cell culture methods and devices utilizing gas permeable materials
US20050221481A1 (en) 2004-03-30 2005-10-06 Istituto Superiore Di Sanita' Amplification of T cells from human cord blood in serum-deprived culture stimulated with stem cell factor, interleukin-7 and interleukin-2
US7785806B2 (en) 2004-04-28 2010-08-31 Vaxdesign Corporation Method for determining the immunogenicity of an antigen
ES2653570T3 (en) 2004-05-27 2018-02-07 The Trustees Of The University Of Pennsylvania Innovative artificial antigen presenting cells and uses thereof
US7785875B2 (en) 2004-07-03 2010-08-31 Mogam Biotechnology Research Institute Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
US20060045883A1 (en) 2004-08-26 2006-03-02 Jeffrey Molldrem Anti-cancer vaccines
JP4731867B2 (en) 2004-10-01 2011-07-27 国立大学法人三重大学 Method for inducing CD8 positive cytotoxic T lymphocytes
US20060204509A1 (en) 2005-03-14 2006-09-14 Harty John T Accelerated CD8+ T-cell memory after dendritic cell vaccination
EP1712615A1 (en) 2005-04-15 2006-10-18 Txcell In vitro production of a cell population using feeder cells
DE602006010934D1 (en) * 2005-04-20 2010-01-21 Hoffmann La Roche Method for identifying epitopes associated with immunogenicity in biopharmaceuticals
CN101252946A (en) 2005-05-11 2008-08-27 宾夕法尼亚大学董事会 Methods for the rapid expansion of antigen specific T-cells
US20070003531A1 (en) 2005-06-30 2007-01-04 University Of Connecticut Methods for improving immunotherapy by enhancing survival of antigen-specific cytotoxic T lymphocytes
US20100035282A1 (en) 2005-08-03 2010-02-11 Maria Chiara Bonini Use of common gamma chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes
JP4824389B2 (en) 2005-10-28 2011-11-30 株式会社医学生物学研究所 Cytotoxic T cell epitope peptide that specifically attacks Epstein-Barr virus infected cells and uses thereof
EP1948232A4 (en) 2005-11-18 2010-09-22 Univ Ohio State Res Found Viral gene products and methods for vaccination to prevent viral associated diseases
GB0604170D0 (en) 2006-03-02 2006-04-12 Antitope Ltd T cell assays
EP1989544B1 (en) 2006-03-02 2011-06-22 Antitope Limited T cell assays
WO2007121276A2 (en) 2006-04-12 2007-10-25 Biocept, Inc. Enrichment of circulating fetal dna
WO2008025992A2 (en) 2006-09-01 2008-03-06 Cambridge Enterprise Limited Methods of expanding non-effector cd8 t-cell populations
CA2670107A1 (en) 2006-11-22 2008-06-05 The Board Of Trustees Of The University Of Arkansas Multi-epitope peptide-loaded dendritic cell immunotherapy for cancer
AU2007332869B2 (en) 2006-12-07 2012-10-11 Wilson Wolf Manufacturing, LLC Highly efficient gas permeable devices and methods for culturing cells
EP2117571B1 (en) 2006-12-08 2017-03-08 Monopar Therapeutics Inc. Urokinase-type plasminogen activator receptor epitope
DE102006060824B4 (en) * 2006-12-21 2011-06-01 Johannes-Gutenberg-Universität Mainz Detection of Individual T Cell Response Patterns Against Tumor-associated Antigens (TAA) in Tumor Patients as a Basis for Individual Therapeutic Vaccination of Patients
EP2205252B1 (en) 2007-09-27 2017-04-05 The Board Of Trustees Of The University Of Arkansas Inhibition of dendritic cell-driven regulatory t cell activation and potentiation of tumor antigen-specific t cell responses by interleukin-15 and map kinase inhibitor
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
WO2009053109A1 (en) 2007-10-24 2009-04-30 Anne Letsch Antigen-specific t-cell preparations from bone marrow
EP2215111B1 (en) 2007-11-01 2016-03-16 Mayo Foundation For Medical Education And Research Hla-dr binding peptides and their uses
EP2065462A1 (en) 2007-11-27 2009-06-03 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens
US20110236363A1 (en) 2008-09-11 2011-09-29 Lung-Ji Chang System and method for producing t cells
CN101824400B (en) 2009-03-05 2012-08-08 中国科学院微生物研究所 Method for amplifying and multiplying T cells with antigenic specificity
US9963677B2 (en) 2009-08-24 2018-05-08 Baylor College Of Medicine Generation of CTL lines with specificity against multiple tumor antigens or multiple viruses
JP5833443B2 (en) 2009-08-29 2015-12-16 株式会社バイオメッドコア Method for measuring antigen-specific T cell inducibility
GB0917090D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
WO2011072088A2 (en) 2009-12-08 2011-06-16 Wilson Wolf Manufacturing Corporation Improved methods of cell culture for adoptive cell therapy
US20130115617A1 (en) 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
US9115402B2 (en) * 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
WO2011146473A1 (en) 2010-05-17 2011-11-24 Duke University Methods of treatment using ex vivo expansion of cord blood t cells
WO2012017033A1 (en) 2010-08-04 2012-02-09 Ieo-Istituto Europeo Di Oncologia S.R.L. Method of antigen loading for immunotherapy
WO2012054792A2 (en) 2010-10-22 2012-04-26 Virginia Commonwealth University Composition and method for immunological treatment of cancer, prevention of cancer recurrence and metastasis, and overcoming immune suppressor cells
EP2453243A1 (en) 2010-11-11 2012-05-16 Cosmo S.p.A. Method for the diagnosis and/or follow up of the evolution of a tumor
US20130045491A1 (en) 2011-07-19 2013-02-21 Derya Unutmaz Methods for activating t cells
MX351226B (en) 2011-09-08 2017-10-05 Yeda Res & Dev Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment.
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
AU2012351347B2 (en) 2011-12-12 2016-05-19 Baylor College Of Medicine Process of expanding T cells
WO2013119947A1 (en) 2012-02-09 2013-08-15 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
US20130217122A1 (en) 2012-02-21 2013-08-22 The Trustees Of The University Of Pennsylvania Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library
WO2013169922A1 (en) 2012-05-08 2013-11-14 Western University Of Health Sciences Standardized ex vivo platforms for the antigen-specific expansion of cd4+ t cell populations
WO2015075175A1 (en) 2013-11-22 2015-05-28 Cellectis Method for generating batches of allogeneic t-cells with averaged potency
EP3097416A2 (en) * 2014-01-21 2016-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for testing t cell priming efficacy in a subject
WO2016073595A1 (en) 2014-11-05 2016-05-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services T cells and dendritic cells for polyomavirus therapy
MY189857A (en) 2014-11-05 2022-03-14 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line and donor thereof for adoptive cellular therapy
US20180072990A1 (en) 2015-03-20 2018-03-15 Children's National Medical Center Generating virus or other antigen-specific t cells from a naïve t cell population
EP3756676B1 (en) 2015-06-26 2023-01-11 Memorial Sloan Kettering Cancer Center Methods of treating cmv retinitis by t cell therapy
CN113943703A (en) 2015-09-18 2022-01-18 贝勒医学院 Identification of immunogenic antigens from pathogens and correlation with clinical efficacy
BR112018073136A2 (en) 2016-05-25 2019-03-12 The Council Of The Queensland Institute Of Medical Research Methods to Treat Autoimmune Disease Using Allogeneic T-Cells
US20190194619A1 (en) 2016-09-16 2019-06-27 Baylor College Of Medicine Platform for activation and expansion of virus-specific t-cells
WO2018055191A1 (en) 2016-09-26 2018-03-29 Tessa Therapeutics Pte. Ltd. T cell expansion method
WO2018232467A1 (en) 2017-06-22 2018-12-27 The Westmead Institute for Medical Research Adoptive t cell therapy 2
KR20200051714A (en) 2017-09-06 2020-05-13 난트 홀딩스 아이피, 엘엘씨 HLA TISSUE MATCHING AND METHODS THEREFOR
GB201808651D0 (en) 2018-05-25 2018-07-11 Rolls Royce Plc Rotor blade arrangement
AU2020247987A1 (en) 2019-03-25 2021-11-11 Baylor College Of Medicine Multi-respiratory virus antigen-specific T cells and methods of making and using the same therapeutically
TW202248419A (en) 2019-05-08 2022-12-16 美商百歐恩泰美國公司 T cell manufacturing compositions and methods
US20220305118A1 (en) 2019-06-20 2022-09-29 Janssen Sciences Ireland Unlimited Company Carbohydrate nanocarrier delivery of hepatitis b virus (hbv) vaccines
US20220257654A1 (en) 2019-07-23 2022-08-18 Baylor College Of Medicine Antigen-specific t cell banks and methods of making and using the same therapeutically
EP4003378A4 (en) 2019-07-29 2023-08-23 Baylor College of Medicine Antigen-specific t cell banks and methods of making and using the same therapeutically
KR20220048021A (en) 2019-08-16 2022-04-19 베이롤 칼리지 오브 메드신 Third party virus-specific T cell compositions, methods for their preparation and methods for their use in antiviral prophylaxis
US20230028788A1 (en) 2019-12-23 2023-01-26 Baylor College Of Medicine T cell performance assay as a prognostic factor for clinical outcome
CA3176244A1 (en) 2020-03-20 2021-09-23 Baylor College Of Medicine Sars-cov2-specific t cell compositions and their use in treating and preventing coronavirus and other respiratory virus infections
EP3974029A1 (en) 2020-09-25 2022-03-30 Universidad Autónoma de Madrid Memory t cells as adoptive cell therapy for viral infections

Also Published As

Publication number Publication date
AU2016324479B2 (en) 2022-12-01
EP3350600A1 (en) 2018-07-25
JP2018529339A (en) 2018-10-11
JP6999941B2 (en) 2022-02-10
US20220001005A1 (en) 2022-01-06
JP2024045272A (en) 2024-04-02
IL258090B2 (en) 2023-04-01
US11167024B2 (en) 2021-11-09
AU2016324479A1 (en) 2018-04-12
CN113791213A (en) 2021-12-14
AU2022268286A1 (en) 2022-12-15
JP7429051B2 (en) 2024-02-07
EP4290238A2 (en) 2023-12-13
IL258090B (en) 2022-12-01
JP2022002511A (en) 2022-01-11
US11931408B2 (en) 2024-03-19
CN108449994A (en) 2018-08-24
EP3350600A4 (en) 2019-04-17
IL298359A (en) 2023-01-01
CA2998649A1 (en) 2017-03-23
WO2017049291A1 (en) 2017-03-23
CN108449994B (en) 2021-10-01
HK1258649A1 (en) 2019-11-15
IL258090A (en) 2018-05-31
CN113943703A (en) 2022-01-18
US20180250384A1 (en) 2018-09-06

Similar Documents

Publication Publication Date Title
HK1258649A1 (en) Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
IL288541A (en) Vaccine against rsv
HK1256169A1 (en) Infectious disease vaccines
IL262109A (en) Vaccine against rsv
PL3868741T3 (en) Composition comprising a pyrimidine compound and a pathogen derived antigen
MA46316A (en) HUMAN CYTOMEGALOVIRUS VACCINE
IL241566B (en) Wt1 antigen peptide conjugate vaccine
GB201410971D0 (en) Vaccine
GB201518684D0 (en) Vaccine
HK1220914A1 (en) Method for improving the efficacy of a survivin vaccine in the treatment of cancer
PL3185899T3 (en) Improved hvt-vectored nd-ibd vaccine
ZA201805547B (en) Novel antigen for use in malaria vaccine
EP3273989C0 (en) Streptococcal vaccine
HK1246659A1 (en) Foot-and-mouth disease vaccine
GB201522132D0 (en) Vaccine
GB2538953B (en) Smart elderly walker
GB201616904D0 (en) Vaccine
IL254824A0 (en) Walker device
PL3188755T3 (en) Vaccine
GB201419061D0 (en) Conjugated Vaccine
GB201417214D0 (en) Vaccine
PT3297666T (en) Molecular adjuvant and vaccine
GB201603029D0 (en) Vaccine
GB201408819D0 (en) Antigen immunogenicity characteristion assay
HU4436U (en) Water-soluble aromatizer device